The U.S. Food and Drug Administration (FDA) has revised the emergency use authorizations (EUAs) for the Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines to simplify the vaccination schedule for most individuals. The updated EUAs authorize the use of the current bivalent vaccines, covering the original strain and the omicron BA.4/BA.5 strains, for all doses given to individuals aged 6 months and older, including additional doses for certain populations. However, the monovalent versions of the Moderna and Pfizer-BioNTech vaccines are no longer authorized for use in the United States. Key Points to Note: Individuals previously vaccinated with a monovalent COVID-19 vaccine who...